DiscoverX Gene Symbol  GPCRs	Assay Mode		PZ-2891 PZ-2891					DiscoverX Gene Symbol			PZ-2891			PZ-2891		
		1 μM % Response			10 μM % Response				Assay Mode		1 μΜ		10 μΜ			
										% Response			% Response			
		Replicate 1	Replicate 2	Average	Replicate 1	Replicate 2	Average	Nuclear Hormone R	eceptors	Replicate 1	Replicate 2	Average	Replicate 1	Replicate 2	Avera	
ADORA2A	Agonist	-14.5	-16.2	-15.4	-19.5	-6.0	-12.8	AR	Agonist	-0.5	-0.5	-0.5	-0.5	-0.5	-0.5	
ADORA2A	Antagonist	-7.4	-13.6	-10.5	-6.4	9.5	1.6	AR	Antagonist	23.4	17.1	20.3	15.9	-3.1	6.4	
ADRA1A	Agonist	-23.7	-25.0	-24.4	-24.6	-24.5	-24.6	GR	Agonist	Acceptance of the second	0.9	0.0	0.1	0.5	0.3	
ADRA1A	Antagonist	-9.2	-6.5	-7.9	0.6	12.4	6.5	GR			-11.1	-1.2	4.9	-15.7	-5.4	
ADRA2A	Agonist	10.5	4.3	7.4	11.2	3.8	7.5	Transporter	THE RESERVE AND PARTY AND PERSONS ASSESSMENT	Replicate 1	Replicate 2	Average	Replicate 1	Replicate 2	Avera	
ADRA2A	Antagonist	-4.9	-3.0	-4.0	-5.1	-7.8	-6.5	DAT	Blocker	-13.1	9.6	-1.8	-3.8	-7.1	-5.	
ADRB1	Agonist	1.1	0.9	1.0	1.0	0.1	0.6	NET	Blocker	22.4	18.6	20.5	20.1	19.5	19.	
ADRB1	Antagonist	7.6	1.3	4.5	11.6	8.6	10.1	SERT	Blocker	2.0	1.0	1.5	3.2	7.3	5.	
ADRB2	Agonist	0.7	0.1	0.4	0.2	0.2	0.2	Ion Channel	_	Replicate 1	Replicate 2	Average	Replicate 1	Replicate 2	Aver	
ADRB2	Antagonist	8.4	9.8	9.1	27.0	23.8	25.4	CAV1.2	Blocker	0.6	-0.6	0.0	7.7	5.9	6.8	
AVPR1A	Agonist	-0.8	-0.5	-0.7	-0.9	-1.2	-1.1	GABAA	Opener	1.7	0.8	1.3	0.0	1.1	0.0	
AVPR1A	Antagonist	0.8	13.2	7.0	8.0	29.0	18.5	GABAA	Blocker	-13.2	-24.1	-18.7	-19.3	-25.7	-22	
CCKAR	Agonist	-5.2	-4.7	-5.0	-4.5	-4.6	-4.6	hERG	Blocker	-36.2	-1.4	-18.8	7.2	-18.4	-5.	
CCKAR	Antagonist	0.9	3.1	2.0	14.6	8.6	11.6	HTR3A	Opener	-10.4	-18.0	-14.2	-2.3	-19.7	-11	
CHRM1	Agonist	-0.4	-0.8	-0.6	-2.2	-1.9	-2.1	HTR3A	Blocker	-7.3	-21.6	-14.5	4.8	4.4	4.0	
CHRM1	Antagonist	1.3	1.5	1.4	13.5	13.1	13.3	NAV1.5	A STATE OF THE PARTY OF THE PARTY.	-22.1	-16.8	-19.5	-19.6	-15.5	-17	
CHRM2	Antagonist	9.8	15.8	12.8	29.5	40.6	35.1	Non-Kinase Enz	Name and Address of the Owner, where the Owner, which is	Replicate 1	Replicate 2	Average	Replicate 1	Replicate 2	Aver	
CHRM2	Antagonist	-7.4	-6.2	-6.8	-7.9	-13.3	-10.6	AChE	Inhibitor	9.1	-0.1	4.5	22.2	17.0	19	
CHRM3	Committee of the Commit	-1.3	-3.3	-2.3	-4.2	-2.7	-3.5	COX1	Inhibitor	****	-7.1	-4.7	13.6	10.1	11	
CHRM3	Agonist Antagonist	1.6	9.3	5.5	6.1	12.3	9.2	COX2	Inhibitor	*************************	-1.3	1.5	23.4	21.6	22.	
CNR1		11.8	15.5	13.7	42.3	38.7	40.5	MAOA	Inhibitor	-0.8	-4.7	-2.8	4.6	2.6	3.	
	Agonist	NAC A TOTAL CONTRACTOR		-2.3	-1.6	-5.6	-3.6	PDE3A	Inhibitor		16.6	16.6	65.4	66.8	66	
CNR1 CNR2	Antagonist Agonist	-2.9 2.7	-1.6 13.8	8.3	10.3	4.2	7.3	PDE4D2	Charles States (407 No. 500 September 2	A CONTRACTOR OF THE PARTY OF TH	-2.3	0.0	0.0	0.0	0.0	
CNR2	SECURE SE	1.4	-0.1	0.7	-0.7	-1.8	-1.3	Kinases	In note of	Replicate 1		Average	Replicate 1	Replicate 2	Aver	
DRD1	Antagonist	1.1	0.6	0.7	-0.6	0.6	0.0	INSR	Inhibitor		0.7	5.7	-3.3	16.0	6.	
DRD1	Agonist	32.9	32.9	32.9	51.3	53.3	52.3	LCK	CONTRACTOR CONTRACTOR PROPERTY.		-18.4	-8.3	-12.4	-3.6	-8.	
DRD2S	Antagonist	and the second second	and the second second	15.4	16.7	21.6	19.2	ROCK1	Inhibitor		-8.5	-10.4	8.5	6.9	7.	
DRD2S	Agonist	8.9	-0.4	-0.6	-1.1	-1.2	-1.2	VEGFR2	Inhibitor	-8.2	0.0	-4.1	2.4	-14.1	-5.	
	Antagonist	-0.8			-2.6	-2.5	-2.6	VEGFRZ	ilination	-0.2	0.0	-4.2	2.4	2712		
EDNRA	Agonist	-2.7	-3.3	-3.0	Account to the second	7.9	6.5									
EDNRA	Antagonist	2.9	0.5	1.7	5.1		Committee of the Commit	% Response Legend								
HRH1	Agonist	-0.8	-0.6	-0.7	-0.9	-0.8	-0.9	x > 95%								
HRH1	Antagonist	5.6	1.4	3.5	7.1	3.0	5.1	95% ≤ x < 90%								
HRH2	A CONTRACTOR OF THE PARTY OF TH	0.2	0.0	0.1	-0.5	-0.2	-0.4 17.1	90% ≤ x < 85%								
HRH2		1.5	4.5	3.0	15.3	18.8	Section 1997	85% ≤ x < 70%								
HTR1A	Agonist	14.8	10.9	12.9	10.1	11.4	10.8 -3.3	x < 70%								
HTR1A	Antagonist	-0.7	-4.8	-2.8	-3.6	-3.0 15.0	13.7	X \ 70%								
HTR1B	The second second second second second	9.5	14.7	12.1	12.3		Contract to the Contract to th									
HTR1B	ALCOHOLOGICA PROBLEM CO.	-0.5	-0.2	-0.4	-1.1 -2.3	-0.8 -1.8	-1.0 -2.1									
HTR2A	Agonist	3.0	-5.9	-1.5												
HTR2A	Antagonist	1.6	7.3	4.5	14.8	14.4	14.6									
HTR2B	CONTRACTOR DESIGNATION OF THE PARTY OF THE P	8.0	9.6	8.8	12.4	7.4	9.9									
HTR2B	CONTRACTOR STATES	17.4	5.6	11.5	28.1	47.5	37.8									
OPRD1	Agonist		18.2	16.5	21.7	17.5	19.6									
OPRD1	ANADOMORPH CONTRACTOR A SERVICE		0.2	0.1	0.2	-1.3	-0.6									
OPRK1	The Company of the Company of the Company		-12.2	-7.1	31.8	33.6	32.7									
OPRK1		-1.3	0.0	-0.7	-1.2	-0.3	-0.8									
OPRM1	Agonist		3.3	1.1	11.0	14.1	12.6									
OPRM1	Antagonist	-0.7	-1.3	-1.0	-2.0	-1.8	-1.9									

Supplementary Dataset 2. Activity of PZ-2891 as a modulator of 72 proteins commonly associated with off-target drug interactions. The SAFETYscan was performed by DiscoverX using the indicated panel of GPCRs, ion channels, nuclear receptors, etc. at both 1 and 10  $\mu$ M PZ-2891.